QualityStocks News - International Stem Cell Corp. Advances Groundbreaking Stem Cell Therapy with Distinct Advantages and Capabilities

Share Article

Company's ability to do something nobody has done before confirms world-leader status.

...new parthenogenetic stem cell lines, by providing a potentially unlimited supply of cells and tissue for transplantation, will be of great benefit to the medical community and patients world-wide.

QualityStocks would like to highlight International Stem Cell Corporation (OTCBB: ISCO), focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).

In the company’s news yesterday,

International Stem Cell Corp. has achieved a critical milestone towards the clinical development of its non-embryonic stem cell therapy.

Through much dedication and hard work, the company’s research and development team has created the world’s first human clinical-grade stem cell lines that can be immune-match to millions of individuals. ISCO’s existing research-grade parthenogenetic stem cell lines, one of which may be an immune-match to approximately 70 million people, are being used in pre-clinical development. ISCO is now in a position to conduct clinical trials in the United States.

“We’ve been working diligently for three years to perfect this technology, which was first developed by our scientific founder, Dr. Elena Revazova in Moscow, and I’m excited to report that we have been able to derive new stem cell lines in the United States under the US and California regulatory frameworks. I’m optimistic that the new parthenogenetic stem cell lines, by providing a potentially unlimited supply of cells and tissue for transplantation, will be of great benefit to the medical community and patients world-wide,” stated Dr. Semechkin, CEO and Co-Chairman of the Board.

Created using ISCO’s proprietary technology, the new stem cell lines represent the first of a new generation of clinical-grade human parthenogenetic stem cell (hpSC) lines created in the United States under US regulatory oversight and designed to meet FDA regulations. The US Food and Drug Administration developed Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards to ensure the safety of products developed for clinical use. Conforming to GMP is necessary to conduct clinical development programs.

Independent third-party testing has confirmed the new lines to be “homozygous” in the HLA coding regions. This means that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection; a distinct clinical advantage over embryonic stem cells. The company anticipates the new lines to immune-match millions of individuals. They will be added to ISCO’s existing bank and provide a platform from which to develop cells and tissue for clinical use.

“The importance of this breakthrough cannot be overstated,” emphasized Dr. Craw, Executive Vice President of ISCO. “Expanding our collection is not only important for our therapeutic programs, but also further establishes our leadership position in human stem cell technology. Achieving this critical milestone moves us along the path to make the transition into a clinical stage company.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website